Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmarylandphysicianscarempc infusion site-of-care Po…
    Ask Trek AI about this page
    CurrentmarylandphysicianscarempcPolicy RX.PA.070.MPC

    Infusion and Injection Services Administered in Unregulated Space (Site-of-Service - Outpatient)

    Customize your policy alerts

    Sign up for marylandphysicianscarempc Policy RX.PA.070.MPC alerts

    Get alerted when Policy RX.PA.070.MPC changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Maryland Physicians Care requirements for where outpatient provider-administered drugs (infusions/injections) should be administered, and when regulated (hospital outpatient) settings are required; applies to MPC Medicaid members and participating and non-participating providers.

    Policy Summary
    Payermarylandphysicianscarempc
    PolicyInfusion and Injection Services Administered in Unregulated Space
    Policy CodePolicy RX.PA.070.MPC
    Change TypeCodes addedclarification of medication review
    Effective DateApr 1, 2023
    Last ReviewApr 1, 2026
    Next Review DateFeb 1, 2026
    Key ActionObtain site-of-care prior authorization for regulated (hospital outpatient) infusion settings and submit supporting medical records documenting need.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Addition of Ocrevus Zunovo

    Revised applicable code list to include multiple immune globulin and biologic J-codes and biosimilars

    Clarified that medications are subject to separate medical necessity review using drug-specific clinical criteria regardless of site of care

    Up to 6 monthsInitial auth length
    Up to 1 yearReauthorization length
    Rural 30 / Suburban 10 / Urban 5Max travel distance
    Multiple J/Q codesReferenced drug codes

    Coverage Criteria — Regulated Infusion & Injection Services

    Regulated Infusion and Injection Service Settings (Initial)

    Regulated outpatient hospital infusion/injection is COVERED when ANY of the following are met (submission of medical records required).

    Complex medical status requiring enhanced monitoring: The individual's complex medical status or therapy requires enhanced monitoring and potential intervention above and beyond the capabilities of the office or home infusion setting

    submission of medical records required

    Prior severe infusion-related adverse events: Documentation (e.g., infusion records, medical records) of episodes of severe or potentially life-threatening infusion-related adverse events (e.g., anaphylaxis, seizure, thromboembolism, myocardial infarction) that have not been responsive to acetaminophen, steroids, diphenhydramine, fluids, infusion rate reductions, or other premedications, thereby increasing risk to the individual when administration is in the home or office setting

    examples provided in policy; supporting records required

    Unsuitable homecare/caregiver/environment: Homecare or infusion provider has deemed that the individual, home caregiver, or home environment is not suitable for home infusion therapy (if the prescriber cannot infuse in the office setting)

    provider assessment and documentation required

    Drug label site restriction: The prescribed medication has a site-of-care restriction for administration per the FDA-approved label

    follow FDA label; documentation required

    Reauthorization Criteria

    Reauthorization for regulated service settings is reviewed annually and covered when ALL of the following are true:

    Reauthorization requirements: Documentation that the individual remains medically inappropriate for administration of the prescribed medication at the alternative sites of care; and all medications will continue to meet drug-specific medical necessity criteria through separate clinical reviewannual review; up to 1 year per renewal

    all medications remain subject to medication-specific clinical criteria; submit supporting records

    MPC requires members to use alternative sites of care for outpatient infusions and injections when appropriate. Alternative sites include non-hospital outpatient infusion centers, physician offices, ambulatory infusion suites, and home infusion services. These locations are considered acceptable places of service for administration of provider‑administered medications and are the preferred setting unless the member meets documented criteria for a regulated (hospital outpatient) infusion setting. Clinical rationale and supporting documentation must be submitted to justify exceptions to receive services in a regulated setting.

    Use of a hospital outpatient (regulated) infusion setting is reserved for members who meet the policy’s specified regulated‑setting criteria (for example: need for enhanced monitoring, prior severe infusion‑related adverse events, unsuitable homecare/caregiver or environment, or an FDA label site restriction). Site‑of‑care prior authorization is required for regulated settings for all providers. Documentation supporting the medical necessity of a regulated setting (including relevant medical records) should be submitted with the request.

    Initial Authorization Criteria

    Initial Authorization Criteria

    Initial authorization for regulated infusion setting

    Initial regulated setting indications: Any one of the regulated setting criteria is met: complex medical status requiring enhanced monitoring; prior severe infusion-related adverse events not responsive to standard rescue measures; unsuitable home caregiver or environment; or FDA label site-of-care restrictioninitial authorization up to 6 months

    submission of medical records required to support the selected criterion

    Reauthorization / Continuation Therapy

    Reauthorization / Continuation Therapy

    Reauthorization/continuation rules

    Continuation requirements: Annual prior authorization renewal with documentation that the patient remains inappropriate for administration at alternative sites of care and that the medication continues to meet drug-specific medical necessity criteriaup to 1 year per renewal

    initial authorizations are granted up to 6 months; reauthorizations up to 1 year; supporting documentation required

    Applicable Codes & Network Standards

    Applicable CPT/HCPCS J- and Q-codes for provider-administered specialty medicationsHCPCSCovered
    J1745Injection, infliximab, excludes biosimilar (Remicade), 10 mg
    Q5103Injection, infliximab-dyyb, biosimilar (Inflectra), 10 mg
    Q5104Injection, infliximab-abda, biosimilar (Renflexis), 10 mg
    Q5121Injection, infliximab-axxq, biosimilar (Avsola), 10 mg
    J3380Injection, vedolizumab (Entyvio), 1 mg
    J2350Injection, ocrelizumab (Ocrevus), 1 mg
    J2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
    J3032Injection, eptinezumab-jjmr (Vyepti), 1 mg
    J2507Injection, pegloticase (Krystexxa), 1 mg
    J1300Injection, eculizumab (Soliris), 10 mg
    1–10 of 28
    1/3
    Network travel distance standards — infusion center access
    Rural maximum travel distance30 miles
    Suburban maximum travel distance10 miles
    Urban maximum travel distance5 miles

    Provider Requirements & Prior Authorization

    Prior Authorization

    Site-of-care prior authorization rules for unregulated settings

    Site-of-care prior authorization is not required when infusion services are administered in unregulated space by participating health professionals, home infusion service providers, or infusion centers contracted to perform infusion services. Non-participating providers, home infusion service providers, and infusion centers must obtain a site-of-care prior authorization from the PA review team before rendering services.

    • PA not required for participating providers, contracted home infusion providers, and contracted infusion centers in unregulated spaces.
    • Non-participating providers and non-contracted infusion centers must obtain site-of-care PA prior to rendering services.
    Prior Authorization

    Medication-specific prior authorization applies regardless of site

    Medications administered in any setting are subject to a separate medication prior authorization and medical necessity review using drug-specific clinical criteria; this requirement applies regardless of the site of care.

    Allowed Sites of Care

    Note

    Use alternative (unregulated) sites of care when appropriate

    Members must use alternative (unregulated) sites of care (e.g., physician office, ambulatory infusion center, home infusion) when appropriate; site-of-care prior authorization is not required for participating/contracted providers in unregulated settings but is required for regulated settings and for non-participating/non-contracted providers prior to rendering services.

    • Encourage use of unregulated sites of care when member meets no regulated-setting criteria
    • Home infusion is available statewide and is not subject to network travel distance requirements
    • Network travel distance standards for infusion center access (when applicable): Rural 30 miles / Suburban 10 miles / Urban 5 miles

    Step Therapy / Drug-Specific Criteria

    StepRequirement
    1Medications are subject to separate medication prior authorization and medical necessity review using drug-specific clinical criteria regardless of site of care; step therapy specifics are not detailed in this policy.

    Definitions

    Site of Care — definitions
    Hospital inpatientPhysical location for infusion administration within an inpatient hospital setting
    Hospital outpatientPhysical location for infusion administration within a hospital outpatient department
    Physician officeInfusions or injections administered in a physician's office setting
    Ambulatory infusion suite/centerDedicated outpatient infusion center or ambulatory infusion suite for administration of injectable therapies
    Home-based settingInfusions or injections administered in the member's home (home infusion services) — available statewide and not subject to network travel distance requirements
    Medically Necessary — definition

    Background

    Many infusion and injection therapies routinely can be administered safely outside the hospital setting. MPC’s rationale is to reserve the hospital outpatient (regulated) infusion setting for patients who need enhanced monitoring or interventions beyond what can be provided in office, ambulatory infusion, or home environments. Accordingly, the policy frames hospital outpatient infusion as an exception—approved only when specific clinical criteria are met and documented—while encouraging use of unregulated sites when clinically appropriate.

    Biosimilars & Specific Products

    Billing Rule

    Infliximab and listed biosimilars included in applicable codes

    Infliximab (J1745) and the listed infliximab biosimilars (Q5103, Q5104, Q5121) are included in the Applicable Codes; these medications remain subject to separate medication-specific medical necessity review.

    • Applicable codes include J1745 and biosimilars Q5103, Q5104, Q5121
    • Medical necessity review using drug-specific clinical criteria still applies

    Revision History & Policy Changes

    2026-04-01code additionLatest

    Addition of Ocrevus Zunovo to the policy (listed in revision log).

    2026-04code list revision

    Revised applicable code list effective 04/2026 to update immune globulin and biologic J-/Q-codes (revision noted on Applicable Codes page).

    2025-06code addition
    Policy Summary
    Payermarylandphysicianscarempc
    PolicyInfusion and Injection Services Administered in Unregulated Space
    Policy CodePolicy RX.PA.070.MPC
    Change TypeCodes addedclarification of medication review
    Effective DateApr 1, 2023
    Last ReviewApr 1, 2026
    Next Review DateFeb 1, 2026
    Key ActionObtain site-of-care prior authorization for regulated (hospital outpatient) infusion settings and submit supporting medical records documenting need.
    SourceLink
    On This Page
    Coverage Criteria — Regulated Infusion & Injection ServicesInitial Authorization CriteriaReauthorization / Continuation TherapyApplicable Codes & Network StandardsProvider Requirements & Prior AuthorizationAllowed Sites of CareStep Therapy / Drug-Specific CriteriaDefinitionsBackgroundBiosimilars & Specific ProductsRevision History & Policy Changes
  1. Medication prior authorization and medical necessity review use clinical criteria specific to the medication requested.
  2. Requirement applies whether the drug is given in regulated (hospital outpatient) or unregulated settings.
  3. Documentation Required

    Provide medical records to support regulated-setting medical necessity

    Submission of medical records is required to support that an outpatient hospital (regulated) setting is medically necessary. Records should document the clinical reason(s) the member meets regulated-setting criteria (for example, evidence of complex medical status, prior severe infusion-related adverse events, or unsuitability of home/caregiver/environment).

    • Include infusion records or medical records documenting severe or life‑threatening infusion-related adverse events not responsive to standard rescue measures.
    • Provide documentation that the individual remains inappropriate for alternative sites of care when requesting reauthorization.
    Denial Risk

    Obtain site-of-care prior authorization for regulated settings and non‑contracted providers

    Site-of-care prior authorization is required for infusion services administered in regulated space for all participating and non‑participating health professionals and infusion centers; services provided in regulated infusion settings without prior authorization may be denied. Non-participating or non-contracted providers must obtain site-of-care PA prior to rendering services in unregulated spaces.

    • PA required for regulated (hospital outpatient) infusion services for all providers.
    • Services in regulated settings without prior authorization may be denied.
    • Non-participating/non-contracted providers must obtain site-of-care PA before providing services in unregulated settings.
    DefinitionServices, supplies, or medicines that are appropriate and necessary for diagnosis or treatment of a medical condition; meet standards of good medical practice in the service area; are not primarily for convenience of the member or provider; and consider the most appropriate level or supply of service that can be safely provided.
    StandardsConsistent with FDA-approved indications and accepted drug compendia as part of determining medical necessity and prior authorization decisions.
    ExclusionsCare provided primarily for convenience of the member or provider is not considered medically necessary.

    Added eculizumab biosimilar products and Vyvgart Hytrulo (noted in revision log 06/2025).

    2025-02content removal

    Removed acute therapy medications including antibiotics and IV iron products (revision log entry 02/2025).

    2024-02annual review

    Annual review performed (revision log entry 02/2024).

    2023-05-22removal

    Removal of Botox products from restriction (revision log entry 05/22/2023).

    2023-04-01new_policy

    Policy originally issued (New Policy effective 04/01/2023).